Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial.

Parker C, Krishnan S, Hamadeh L, Irving JAE, Kuiper RP, Révész T, Hoogerbrugge P, Hancock J, Sutton R, Moorman AV, Saha V.

Lancet Haematol. 2019 Apr;6(4):e204-e216. doi: 10.1016/S2352-3026(19)30003-1. Epub 2019 Feb 27.

2.

Combined sialic acid and histone deacetylase (HDAC) inhibitor treatment up-regulates the neuroblastoma antigen GD2.

van den Bijgaart RJE, Kroesen M, Wassink M, Brok IC, Kers-Rebel ED, Boon L, Heise T, van Scherpenzeel M, Lefeber DJ, Boltje TJ, den Brok MH, Hoogerbrugge PM, Büll C, Adema GJ.

J Biol Chem. 2019 Mar 22;294(12):4437-4449. doi: 10.1074/jbc.RA118.002763. Epub 2019 Jan 22.

PMID:
30670592
3.

Tumor suppressor BTG1 limits activation of BCL6 expression downstream of ETV6-RUNX1.

Tijchon E, van Emst L, Yuniati L, van Ingen Schenau D, Gerritsen M, van der Meer LT, Williams O, Hoogerbrugge PM, Scheijen B, van Leeuwen FN.

Exp Hematol. 2018 Apr;60:57-62.e3. doi: 10.1016/j.exphem.2018.01.006. Epub 2018 Feb 8.

PMID:
29408281
4.

High Yield of Pathogenic Germline Mutations Causative or Likely Causative of the Cancer Phenotype in Selected Children with Cancer.

Diets IJ, Waanders E, Ligtenberg MJ, van Bladel DAG, Kamping EJ, Hoogerbrugge PM, Hopman S, Olderode-Berends MJ, Gerkes EH, Koolen DA, Marcelis C, Santen GW, van Belzen MJ, Mordaunt D, McGregor L, Thompson E, Kattamis A, Pastorczak A, Mlynarski W, Ilencikova D, van Silfhout AV, Gardeitchik T, de Bont ES, Loeffen J, Wagner A, Mensenkamp AR, Kuiper RP, Hoogerbrugge N, Jongmans MC.

Clin Cancer Res. 2018 Apr 1;24(7):1594-1603. doi: 10.1158/1078-0432.CCR-17-1725. Epub 2018 Jan 19.

5.

Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.

Scheijen B, Boer JM, Marke R, Tijchon E, van Ingen Schenau D, Waanders E, van Emst L, van der Meer LT, Pieters R, Escherich G, Horstmann MA, Sonneveld E, Venn N, Sutton R, Dalla-Pozza L, Kuiper RP, Hoogerbrugge PM, den Boer ML, van Leeuwen FN.

Haematologica. 2017 Mar;102(3):541-551. doi: 10.3324/haematol.2016.153023. Epub 2016 Dec 15.

6.

Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences.

Waanders E, Scheijen B, Jongmans MC, Venselaar H, van Reijmersdal SV, van Dijk AH, Pastorczak A, Weren RD, van der Schoot CE, van de Vorst M, Sonneveld E, Hoogerbrugge N, van der Velden VH, Gruhn B, Hoogerbrugge PM, van Dongen JJ, Geurts van Kessel A, van Leeuwen FN, Kuiper RP.

Leukemia. 2017 Apr;31(4):821-828. doi: 10.1038/leu.2016.277. Epub 2016 Oct 13.

PMID:
27733777
7.

Real-world implementation of electronic patient-reported outcomes in outpatient pediatric cancer care.

Schepers SA, Sint Nicolaas SM, Haverman L, Wensing M, Schouten van Meeteren AYN, Veening MA, Caron HN, Hoogerbrugge PM, Kaspers GJL, Verhaak CM, Grootenhuis MA.

Psychooncology. 2017 Jul;26(7):951-959. doi: 10.1002/pon.4242. Epub 2016 Sep 4.

PMID:
27502744
8.

In Vivo Imaging of Antileukemic Drug Asparaginase Reveals a Rapid Macrophage-Mediated Clearance from the Bone Marrow.

van der Meer LT, Terry SY, van Ingen Schenau DS, Andree KC, Franssen GM, Roeleveld DM, Metselaar JM, Reinheckel T, Hoogerbrugge PM, Boerman OC, van Leeuwen FN.

J Nucl Med. 2017 Feb;58(2):214-220. doi: 10.2967/jnumed.116.177741. Epub 2016 Aug 4.

9.

Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma.

Kroesen M, Büll C, Gielen PR, Brok IC, Armandari I, Wassink M, Looman MW, Boon L, den Brok MH, Hoogerbrugge PM, Adema GJ.

Oncoimmunology. 2016 Mar 28;5(6):e1164919. doi: 10.1080/2162402X.2016.1164919. eCollection 2016 Jun.

10.

Predicting trajectories of behavioral adjustment in children diagnosed with acute lymphoblastic leukemia.

Sint Nicolaas SM, Hoogerbrugge PM, van den Bergh EM, Custers JA, Gameiro S, Gemke RJ, Verhaak CM.

Support Care Cancer. 2016 Nov;24(11):4503-13. doi: 10.1007/s00520-016-3289-9. Epub 2016 Jun 14.

11.

Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group.

Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, Egeler RM, Hoogerbrugge P, Kaspers G, Van der Schoot E, De Haas V, Van Dongen J.

J Clin Oncol. 2016 Aug 1;34(22):2591-601. doi: 10.1200/JCO.2015.64.6364. Epub 2016 Jun 6.

PMID:
27269950
12.

Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia.

Irving JA, Enshaei A, Parker CA, Sutton R, Kuiper RP, Erhorn A, Minto L, Venn NC, Law T, Yu J, Schwab C, Davies R, Matheson E, Davies A, Sonneveld E, den Boer ML, Love SB, Harrison CJ, Hoogerbrugge PM, Revesz T, Saha V, Moorman AV.

Blood. 2016 Aug 18;128(7):911-22. doi: 10.1182/blood-2016-03-704973. Epub 2016 May 26.

13.

AGORA, a data- and biobank for birth defects and childhood cancer.

van Rooij IA, van der Zanden LF, Bongers EM, Renkema KY, Wijers CH, Thonissen M, Dokter EM, Marcelis CL, de Blaauw I, Wijnen MH, Hoogerbrugge PM, Bokkerink JP, Schreuder MF, Koster-Kamphuis L, Cornelissen EA, Kapusta L, van Heijst AF, Liem KD, de Gier RP, Kuijpers-Jagtman AM, Admiraal RJ, Bergé SJ, van der Biezen JJ, Verdonck A, Vander Poorten V, Hens G, Roosenboom J, Lilien MR, de Jong TP, Broens P, Wijnen R, Brooks A, Franke B, Brunner HG, Carels CE, Knoers NV, Feitz WF, Roeleveld N.

Birth Defects Res A Clin Mol Teratol. 2016 Aug;106(8):675-84. doi: 10.1002/bdra.23512. Epub 2016 May 6.

PMID:
27150573
14.

Tumor suppressors BTG1 and BTG2 regulate early mouse B-cell development.

Tijchon E, van Emst L, Yuniati L, van Ingen Schenau D, Havinga J, Rouault JP, Hoogerbrugge PM, van Leeuwen FN, Scheijen B.

Haematologica. 2016 Jul;101(7):e272-6. doi: 10.3324/haematol.2015.139675. Epub 2016 Apr 1. No abstract available.

15.

Recognition of genetic predisposition in pediatric cancer patients: An easy-to-use selection tool.

Jongmans MC, Loeffen JL, Waanders E, Hoogerbrugge PM, Ligtenberg MJ, Kuiper RP, Hoogerbrugge N.

Eur J Med Genet. 2016 Mar;59(3):116-25. doi: 10.1016/j.ejmg.2016.01.008. Epub 2016 Jan 26. Review.

16.

Screening for Psychosocial Risk in Dutch Families of a Child With Cancer: Reliability, Validity, and Usability of the Psychosocial Assessment Tool.

Sint Nicolaas SM, Schepers SA, Hoogerbrugge PM, Caron HN, Kaspers GJ, van den Heuvel-Eibrink MM, Grootenhuis MA, Verhaak CM.

J Pediatr Psychol. 2016 Aug;41(7):810-9. doi: 10.1093/jpepsy/jsv119. Epub 2015 Dec 29.

PMID:
26715054
17.

Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia.

Marke R, Havinga J, Cloos J, Demkes M, Poelmans G, Yuniati L, van Ingen Schenau D, Sonneveld E, Waanders E, Pieters R, Kuiper RP, Hoogerbrugge PM, Kaspers GJ, van Leeuwen FN, Scheijen B.

Leukemia. 2016 Jul;30(7):1599-603. doi: 10.1038/leu.2015.359. Epub 2015 Dec 29. No abstract available.

PMID:
26713593
18.

Tumor suppressor BTG1 promotes PRMT1-mediated ATF4 function in response to cellular stress.

Yuniati L, van der Meer LT, Tijchon E, van Ingen Schenau D, van Emst L, Levers M, Palit SA, Rodenbach C, Poelmans G, Hoogerbrugge PM, Shan J, Kilberg MS, Scheijen B, van Leeuwen FN.

Oncotarget. 2016 Jan 19;7(3):3128-43. doi: 10.18632/oncotarget.6519.

19.

Aggravated bone density decline following symptomatic osteonecrosis in children with acute lymphoblastic leukemia.

den Hoed MA, Pluijm SM, te Winkel ML, de Groot-Kruseman HA, Fiocco M, Hoogerbrugge P, Leeuw JA, Bruin MC, van der Sluis IM, Bresters D, Lequin MH, Roos JC, Veerman AJ, Pieters R, van den Heuvel-Eibrink MM.

Haematologica. 2015 Dec;100(12):1564-70. doi: 10.3324/haematol.2015.125583. Epub 2015 Sep 24.

20.

Sharing decisions during diagnostic consultations; an observational study in pediatric oncology.

Wiering BM, Noordman J, Tates K, Zwaanswijk M, Elwyn G, De Bont ES, Beishuizen A, Hoogerbrugge PM, Van Dulmen S.

Patient Educ Couns. 2016 Jan;99(1):61-7. doi: 10.1016/j.pec.2015.07.026. Epub 2015 Jul 29.

PMID:
26298218
21.

Targeted Deletion of Btg1 and Btg2 Results in Homeotic Transformation of the Axial Skeleton.

Tijchon E, van Ingen Schenau D, van Opzeeland F, Tirone F, Hoogerbrugge PM, Van Leeuwen FN, Scheijen B.

PLoS One. 2015 Jul 28;10(7):e0131481. doi: 10.1371/journal.pone.0131481. eCollection 2015.

22.

Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study.

Boer JM, van der Veer A, Rizopoulos D, Fiocco M, Sonneveld E, de Groot-Kruseman HA, Kuiper RP, Hoogerbrugge P, Horstmann M, Zaliova M, Palmi C, Trka J, Fronkova E, Emerenciano M, do Socorro Pombo-de-Oliveira M, Mlynarski W, Szczepanski T, Nebral K, Attarbaschi A, Venn N, Sutton R, Schwab CJ, Enshaei A, Vora A, Stanulla M, Schrappe M, Cazzaniga G, Conter V, Zimmermann M, Moorman AV, Pieters R, den Boer ML.

Leukemia. 2016 Jan;30(1):32-8. doi: 10.1038/leu.2015.199. Epub 2015 Jul 23.

PMID:
26202931
23.

Independent development of lymphoid and histiocytic malignancies from a shared early precursor.

Waanders E, Hebeda KM, Kamping EJ, Groenen PJ, Simons A, Hoischen A, Jongmans MC, Hoogerbrugge PM, van Leeuwen FN, Kuiper RP, Te Loo DM.

Leukemia. 2016 Apr;30(4):955-8. doi: 10.1038/leu.2015.193. Epub 2015 Jul 23. No abstract available.

PMID:
26202925
24.

Illness cognitions and family adjustment: psychometric properties of the Illness Cognition Questionnaire for parents of a child with cancer.

Sint Nicolaas SM, Schepers SA, van den Bergh EMM, Evers AWM, Hoogerbrugge PM, Grootenhuis MA, Verhaak CM.

Support Care Cancer. 2016 Feb;24(2):529-537. doi: 10.1007/s00520-015-2795-5. Epub 2015 Jun 25.

25.

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.

Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M; EURAMOS-1 investigators.

J Clin Oncol. 2015 Jul 10;33(20):2279-87. doi: 10.1200/JCO.2014.60.0734. Epub 2015 Jun 1. Erratum in: J Clin Oncol. 2016 Nov 20;34(33):4059.

26.

A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment.

Hagleitner MM, Coenen MJ, Gelderblom H, Makkinje RR, Vos HI, de Bont ES, van der Graaf WT, Schreuder HW, Flucke U, van Leeuwen FN, Hoogerbrugge PM, Guchelaar HJ, te Loo DM.

Clin Cancer Res. 2015 Aug 1;21(15):3436-41. doi: 10.1158/1078-0432.CCR-14-2638. Epub 2015 Mar 31.

27.

TRPM7 maintains progenitor-like features of neuroblastoma cells: implications for metastasis formation.

Middelbeek J, Visser D, Henneman L, Kamermans A, Kuipers AJ, Hoogerbrugge PM, Jalink K, van Leeuwen FN.

Oncotarget. 2015 Apr 20;6(11):8760-76.

28.

Intra-adrenal murine TH-MYCN neuroblastoma tumors grow more aggressive and exhibit a distinct tumor microenvironment relative to their subcutaneous equivalents.

Kroesen M, Brok IC, Reijnen D, van Hout-Kuijer MA, Zeelenberg IS, Den Brok MH, Hoogerbrugge PM, Adema GJ.

Cancer Immunol Immunother. 2015 May;64(5):563-72. doi: 10.1007/s00262-015-1663-y. Epub 2015 Feb 17.

29.

Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.

Hagleitner MM, Coenen MJ, Patino-Garcia A, de Bont ES, Gonzalez-Neira A, Vos HI, van Leeuwen FN, Gelderblom H, Hoogerbrugge PM, Guchelaar HJ, Te Loo MW.

PLoS One. 2014 Dec 31;9(12):e115869. doi: 10.1371/journal.pone.0115869. eCollection 2014.

30.

A germ line mutation in cathepsin B points toward a role in asparaginase pharmacokinetics.

van der Meer LT, Waanders E, Levers M, Venselaar H, Roeleveld D, Boos J, Lanvers C, Brüggemann RJ, Kuiper RP, Hoogerbrugge PM, van Leeuwen FN, te Loo DM.

Blood. 2014 Nov 6;124(19):3027-9. doi: 10.1182/blood-2014-06-582627. No abstract available.

PMID:
25377564
31.

The negative impact of being underweight and weight loss on survival of children with acute lymphoblastic leukemia.

den Hoed MA, Pluijm SM, de Groot-Kruseman HA, te Winkel ML, Fiocco M, van den Akker EL, Hoogerbrugge P, van den Berg H, Leeuw JA, Bruin MC, Bresters D, Veerman AJ, Pieters R, van den Heuvel-Eibrink MM.

Haematologica. 2015 Jan;100(1):62-9. doi: 10.3324/haematol.2014.110668. Epub 2014 Oct 10.

32.

Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia--prospective open cohort analyses of the ALLR3 trial.

Masurekar AN, Parker CA, Shanyinde M, Moorman AV, Hancock JP, Sutton R, Ancliff PJ, Morgan M, Goulden NJ, Fraser C, Hoogerbrugge PM, Revesz T, Darbyshire PJ, Krishnan S, Love SB, Saha V.

PLoS One. 2014 Oct 3;9(10):e108107. doi: 10.1371/journal.pone.0108107. eCollection 2014.

33.

HDAC inhibitors and immunotherapy; a double edged sword?

Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ.

Oncotarget. 2014 Aug 30;5(16):6558-72. Review.

34.

The optimal use of PEG-asparaginase in relapsed ALL--lessons from the ALLR3 Clinical Trial.

Masurekar A, Fong C, Hussein A, Revesz T, Hoogerbrugge PM, Love S, Ciria C, Parker C, Krishnan S, Saha V.

Blood Cancer J. 2014 Apr 25;4:e203. doi: 10.1038/bcj.2014.26. No abstract available.

35.

Self-perception and quality of life in adolescents during treatment for a primary malignant bone tumour.

van Riel CA, Meijer-van den Bergh EE, Kemps HL, Feuth T, Schreuder HW, Hoogerbrugge PM, De Groot IJ, Mavinkurve-Groothuis AM.

Eur J Oncol Nurs. 2014 Jun;18(3):267-72. doi: 10.1016/j.ejon.2014.01.005. Epub 2014 Mar 18.

PMID:
24656419
36.

Patient reported outcomes in pediatric oncology practice: suggestions for future usage by parents and pediatric oncologists.

Schepers SA, Engelen VE, Haverman L, Caron HN, Hoogerbrugge PM, Kaspers GJ, Egeler RM, Grootenhuis MA.

Pediatr Blood Cancer. 2014 Sep;61(9):1707-10. doi: 10.1002/pbc.25034. Epub 2014 Mar 20.

PMID:
24648289
37.

A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.

Kroesen M, Nierkens S, Ansems M, Wassink M, Orentas RJ, Boon L, den Brok MH, Hoogerbrugge PM, Adema GJ.

Int J Cancer. 2014 Mar 15;134(6):1335-45. doi: 10.1002/ijc.28463. Epub 2013 Sep 14.

38.

Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.

van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ, Harrison CJ, Evans WE, van der Velden VH, Hoogerbrugge PM, Van Leeuwen F, Escherich G, Horstmann MA, Mohammadi Khankahdani L, Rizopoulos D, De Groot-Kruseman HA, Sonneveld E, Kuiper RP, Den Boer ML.

Blood. 2013 Oct 10;122(15):2622-9. doi: 10.1182/blood-2012-10-462358. Epub 2013 Aug 23.

39.

Adequate endocrine and cardiovascular response to social stress in survivors of childhood acute lymphoblastic leukemia.

Gordijn MS, Gemke RJ, Bierings MB, Hoogerbrugge PM, Tersteeg-Kamperman MD, Heijnen CJ, Rotteveel J, Kaspers GJ.

Psychoneuroendocrinology. 2013 Dec;38(12):3145-9. doi: 10.1016/j.psyneuen.2013.07.013. Epub 2013 Aug 5.

PMID:
23972944
40.

The role of the MTHFR 677C>T polymorphism in methotrexate-induced liver toxicity: a meta-analysis in patients with cancer.

Hagleitner MM, Coenen MJ, Aplenc R, Patiño-Garcia A, Chiusolo P, Gemmati D, De Mattei M, Ongaro A, Krajinovic M, Hoogerbrugge PM, Vermeulen SH, te Loo DM.

Pharmacogenomics J. 2014 Apr;14(2):115-9. doi: 10.1038/tpj.2013.19. Epub 2013 May 7.

PMID:
23648444
41.

High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.

Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, van der Velden VH, Venn NC, van den Berg H, de Bont ES, Maarten Egeler R, Hoogerbrugge PM, Kaspers GJ, Bierings MB, van der Schoot E, van Dongen J, Law T, Cross S, Mueller H, de Haas V, Haber M, Révész T, Alvaro F, Suppiah R, Norris MD, Pieters R.

Leukemia. 2013 Jul;27(7):1497-503. doi: 10.1038/leu.2013.44. Epub 2013 Feb 14.

PMID:
23407458
42.

Absolute lymphocyte count predicts the response to new influenza virus H1N1 vaccination in pediatric cancer patients.

Mavinkurve-Groothuis AM, van der Flier M, Stelma F, van Leer-Buter C, Preijers FW, Hoogerbrugge PM.

Clin Vaccine Immunol. 2013 Jan;20(1):118-21. doi: 10.1128/CVI.00585-12. Epub 2012 Nov 21.

43.

Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study.

Mavinkurve-Groothuis AM, Marcus KA, Pourier M, Loonen J, Feuth T, Hoogerbrugge PM, de Korte CL, Kapusta L.

Eur Heart J Cardiovasc Imaging. 2013 Jun;14(6):562-9. doi: 10.1093/ehjci/jes217. Epub 2012 Oct 29.

PMID:
23109647
44.

Sleep, fatigue, depression, and quality of life in survivors of childhood acute lymphoblastic leukemia.

Gordijn MS, van Litsenburg RR, Gemke RJ, Huisman J, Bierings MB, Hoogerbrugge PM, Kaspers GJ.

Pediatr Blood Cancer. 2013 Mar;60(3):479-85. doi: 10.1002/pbc.24261. Epub 2012 Aug 8.

PMID:
22887764
45.

Immunocombination therapy for high-risk neuroblastoma.

Kroesen M, Lindau D, Hoogerbrugge P, Adema GJ.

Immunotherapy. 2012 Feb;4(2):163-74. doi: 10.2217/imt.11.169. Review.

PMID:
22394368
46.

Hypothalamic-pituitary-adrenal axis function in survivors of childhood acute lymphoblastic leukemia and healthy controls.

Gordijn MS, van Litsenburg RR, Gemke RJ, Bierings MB, Hoogerbrugge PM, van de Ven PM, Heijnen CJ, Kaspers GJ.

Psychoneuroendocrinology. 2012 Sep;37(9):1448-56. doi: 10.1016/j.psyneuen.2012.01.014. Epub 2012 Mar 2.

PMID:
22385687
47.

The origin and nature of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution.

Waanders E, Scheijen B, van der Meer LT, van Reijmersdal SV, van Emst L, Kroeze Y, Sonneveld E, Hoogerbrugge PM, van Kessel AG, van Leeuwen FN, Kuiper RP.

PLoS Genet. 2012;8(2):e1002533. doi: 10.1371/journal.pgen.1002533. Epub 2012 Feb 16.

48.

Importance of neutropenia for development of invasive infections at various phases of treatment for hemato-oncological diseases in children.

Zwitserloot AM, Mavinkurve-Groothuis AM, Galama JM, Verweij PE, Hoogerbrugge PM, Warris A.

Scand J Infect Dis. 2012 May;44(5):355-62. doi: 10.3109/00365548.2011.641505. Epub 2012 Jan 4.

PMID:
22216875
49.

Favorable outcome of chronic disseminated candidiasis in four pediatric patients with hematological malignancies.

Donker AE, Mavinkurve-Groothuis AM, van Die LE, Verweij PE, Hoogerbrugge PM, Warris A.

Med Mycol. 2012 Apr;50(3):315-9. doi: 10.3109/13693786.2011.588256. Epub 2011 Nov 22.

PMID:
22103343
50.

Age as prognostic factor in patients with osteosarcoma.

Hagleitner MM, Hoogerbrugge PM, van der Graaf WT, Flucke U, Schreuder HW, te Loo DM.

Bone. 2011 Dec;49(6):1173-7. doi: 10.1016/j.bone.2011.08.014. Epub 2011 Aug 26.

PMID:
21893224

Supplemental Content

Loading ...
Support Center